10-QHealthcare

Arcus Biosciences, Inc.

RCUS · Period ending 2026-09-30 · Filed 2026-11-04 · Updated

In short

Arcus Biosciences, Inc. (RCUS) has revenue down 4.3% to $247.0M and net income down 24.7% to -$353.0M year on year. Fisclear flags 2 high-severity risks, led by: Net loss of $353.0M — the company spent more than it earned. Investors should monitor the path to profitability. How we calculate this

Valuation

Healthcare
Live · Yahoo Finance

Price

$15.62

P/B

5.6x

Price ÷ book value

P/S (TTM)

22.5x

Price ÷ revenue per share

Beta

1.09

Moderate market correlation

52-Week Range

$15.56$15.62 now$31.74

Decision Context

Below-average scores in Quality, Efficiency, Cashflow. The data points to fundamental challenges that outweigh near-term macro considerations.

Based on filing period ending Sept 2026

FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.

RCUS vs

Macro Context

Fed Funds Rate

3.88%

Accommodative

10-Year Treasury

5.13%

2026-10-01

Unemployment

4.2%

Near full employment

CPI Index

336.3

2026-09-01

M2 Money Supply

$23.4T

2026-09-01

The Federal Funds rate stands at 3.88% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 5.13%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.2%; Industrial production index is at 104.0; M2 money supply is $23.4T; CPI index stands at 336.3.

SWOT Analysis — RCUS

Inflationary Boom
Macro lens (Inflationary Boom): Rising costs and tighter margins amplify financial risks in this regime.
✦

Strengths

No standout strengths identified from the filing.

◈

Weaknesses

  • Operating Cash Flow: -$482.0M (-183.5% YoY) — Negative operating cash flow — the business consumed more cash than it produced from operations.

  • Net Income: -$353.0M (-24.7% YoY) — The company posted a net loss — total expenses exceeded total revenue.

  • EPS (Diluted): $-3.29 (-4.8% YoY) — Negative EPS — the company recorded a loss on a per-share basis.

  • Revenue: $247.0M (-4.3% YoY) — Revenue fell 4% — the company generated less from its core operations.

  • Total Assets: $1.1B (-1.0% YoY) — Total assets shrank 1% — the balance sheet contracted.

  • R&D spending is 212% of revenue — heavy investment in future growth, but also a drag on current profitability.

◎

Opportunities

No clear opportunities identified at this time.

⚠

Threats

  • Net loss of $353.0M — the company spent more than it earned. Investors should monitor the path to profitability.

  • Negative operating cash flow of $482.0M — the core business consumed more cash than it generated.

Year-over-Year Changes

Operating Cash Flow

-$482.0M

was -$170.0M

−183.5%

Negative operating cash flow — the business consumed more cash than it produced from operations.

Net Income

-$353.0M

was -$283.0M

−24.7%

The company posted a net loss — total expenses exceeded total revenue.

EPS (Diluted)

$-3.29

was $-3.14

−4.8%

Negative EPS — the company recorded a loss on a per-share basis.

Revenue

$247.0M

was $258.0M

−4.3%

Revenue fell 4% — the company generated less from its core operations.

Total Assets

$1.1B

was $1.1B

−1.0%

Total assets shrank 1% — the balance sheet contracted.

Risk Flags

2 high · 0 medium · 1 low
  • ⚠ High

    Net loss of $353.0M — the company spent more than it earned. Investors should monitor the path to profitability.

  • ⚠ High

    Negative operating cash flow of $482.0M — the core business consumed more cash than it generated.

  • ○ Low

    R&D spending is 212% of revenue — heavy investment in future growth, but also a drag on current profitability.

Technical Signals

Daily closes · 1-year data

Arcus Biosciences, Inc.: common questions

Is Arcus Biosciences, Inc. profitable?

No. Arcus Biosciences, Inc. reported a net loss of $353M in its latest fiscal year (fiscal 2025).

Is Arcus Biosciences, Inc.'s revenue growing?

No. Revenue fell 4.3% year on year, to $247.0M.

What is Arcus Biosciences, Inc.'s P/E ratio?

Arcus Biosciences, Inc. has no meaningful P/E ratio at the moment, because it lost money over the latest year. P/E only works when earnings are positive.

Does Arcus Biosciences, Inc. pay a dividend?

No dividend is currently expected from Arcus Biosciences, Inc., according to the latest market data.

What are the main risks for Arcus Biosciences, Inc.?

Fisclear's checks flag 2 medium- or high-severity risks. The most serious: Net loss of $353.0M — the company spent more than it earned. Investors should monitor the path to profitability.

Answers are generated from the figures in this report (updated 5 Nov 2026). Information, not investment advice.

Latest News

via Finnhub

Filing History — RCUS

Get the weekly digest

5 company reports + macro context every week, free. No spam.

  • Unlimited goal simulations
  • 5 free company report summaries per day
  • Weekly financial insights newsletter

External Links

Trade RCUS

Links open broker research pages. Not an endorsement or recommendation.

Research Arcus Biosciences, Inc.

Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.